Inclisiran and cardiovascular events: a patient-level analysis of phase III trials.

Kausik K RayFrederick J RaalDavid G KallendMark J JarosWolfgang KoenigLawrence A LeiterUlf Landmesser Gregory G SchwartzDavid LawrenceAndrew FriedmanLorena Garcia CondeR Scott Wrightnull null

Published in: European heart journal (2022)

This analysis offers early insights into the potential CV benefits of lowering LDL-C with inclisiran and suggests potential benefits for MACE reduction. These findings await confirmation in the larger CV outcomes trials of longer duration.

Keyphrases

cardiovascular events
phase iii
coronary artery disease
open label
clinical trial
cardiovascular disease
case report
double blind
phase ii
randomized controlled trial
risk assessment
study protocol